What the FDA and EMA joint AI principles mean for regulatory submissions (opens in new tab)

Last week, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) shared a statement outlining 10 guiding principles for using AI to generate evidence across the drug product life cycle. This is a clear signal: regulators want to support AI in drug development, but they also want teams to